Cefuroxime compared to piperacillin/tazobactam as empirical treatment of Escherichia coli bacteremia in a low Extended-spectrum beta-lactamase (ESBL) prevalence cohort

Sara Thønnings1 Department of Clinical Microbiology, Copenhagen University Hospital, Hvidovre, Denmark;2 Toxicology Laboratory, Analytical BioSciences, Department of Pharmacy, University of Copenhagen, Copenhagen, DenmarkCorrespondence[email protected]

Filip Jansåker1 Department of Clinical Microbiology, Copenhagen University Hospital, Hvidovre, Denmark;3 Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark

Kim Oren Gradel4 Center for Clinical Epidemiology, Odense University Hospital, Odense, Denmark;5 Research Unit of Clinical Epidemiology, Institute of Clinical Research, University of Southern Denmark, Odense, Denmark

Bjarne Styrishave2 Toxicology Laboratory, Analytical BioSciences, Department of Pharmacy, University of Copenhagen, Copenhagen, Denmark

Jenny Dahl Knudsen1 Department of Clinical Microbiology, Copenhagen University Hospital, Hvidovre, Denmark

Citations (3)

Keep up to date with the latest research on this topic with citation updates for this article.

Cefuroxime compared to piperacillin/tazobactam as empirical treatment of Escherichia coli bacteremia in a low Extended-spectrum beta-lactamase (ESBL) prevalence cohort

Articles from other publishers (3)

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Cefuroxime compared to piperacillin/tazobactam as empirical treatment of Escherichia coli bacteremia in a low Extended-spectrum beta-lactamase (ESBL) prevalence cohort

Citations (3)

Articles from other publishers (3)

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date